{
      "Rank": 220,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Basic medication: Decitabine; Allogeneic umbilical cord mesenchymal stem cells.",
            "Basic medication: Decitabine; placebo: saline."
      ],
      "ArmGroupInterventionName": [
            "Biological: Allogeneic umbilical cord mesenchymal stem cells",
            "Drug: Decitabine",
            "Drug: Decitabine"
      ],
      "ArmGroupLabel": [
            "Experimental group",
            "Control group"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT03184935"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The purposes of the study is to determine the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating Myelodysplastic Syndrome patients."
      ],
      "BriefTitle": [
            "Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife\u00ae-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "December 2023"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Myelodysplastic Syndromes"
      ],
      "ConditionAncestorId": [
            "D000004194",
            "D000010335",
            "D000001855",
            "D000006402",
            "D000011230",
            "D000009369"
      ],
      "ConditionAncestorTerm": [
            "Disease",
            "Pathologic Processes",
            "Bone Marrow Diseases",
            "Hematologic Diseases",
            "Precancerous Conditions",
            "Neoplasms"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC23",
            "All",
            "BC04",
            "BC15",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Symptoms and General Pathology",
            "All Conditions",
            "Neoplasms",
            "Blood and Lymph Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Syndrome",
            "Myelodysplastic Syndrome",
            "Myelodysplastic Syndrome",
            "Myelodysplastic Syndrome"
      ],
      "ConditionBrowseLeafId": [
            "M15507",
            "M13316",
            "M11297",
            "M4286",
            "M8642",
            "M13263",
            "T3993"
      ],
      "ConditionBrowseLeafName": [
            "Syndrome",
            "Preleukemia",
            "Myelodysplastic Syndromes",
            "Bone Marrow Diseases",
            "Hematologic Diseases",
            "Precancerous Conditions",
            "Myelodysplastic Syndromes"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "high"
      ],
      "ConditionMeshId": [
            "D000011289",
            "D000009190",
            "D000013577"
      ],
      "ConditionMeshTerm": [
            "Preleukemia",
            "Myelodysplastic Syndromes",
            "Syndrome"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Double"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Investigator"
      ],
      "DetailedDescription": [
            "This is a randomized, double-blind, paralleled study. 40 patients will be separated into two groups, and receive basic treatment (Decitabine). Patients in experimental group will receive hUC-MSC, while control group receive placebo (normal saline), four weeks as a course of treatment. All of the patients accept examination before treatment, including\n\ndiagnostic projects: bone marrow test, peripheral blood classification, chromosome, and MDS fusion gene test, etc.;\nroutine examination: blood, urine, and stool routine test, X-ray film in chest, electrocardiogram, etc.;\nstem cell-based medicinal products usage, dosage, time, and course of treatment.\n\nThen, patients will accept routine examination everyday, and after treatment, investigator will follow-up for 6 months, to evaluate the security and efficacy of hUC-MSC."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nMDS patients with international prostate symptom score is moderate or severe symptoms\n\nExclusion Criteria:\n\nwith serious renal function impaired\nwith other organ function abnormal: acute hepatitis B, ejection fraction < 40%, serum bilirubin > 3mg/dl, liver function tests abnormal, central nervous system disease, mental disease\nbad physical condition (Karmofsky < 60%)\nwithout signing informed consent form\nunder other therapy that possibly influence MSC security or efficacy\nHIV or other serious disease infection\nDonor: HIV, active hepatitis B/C infection, Syphilitic antibody positive\nDonor/ participants: alcoholism, drug addicted, mental disease"
      ],
      "EnrollmentCount": [
            "40"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000000964",
            "D000000963",
            "D000045504",
            "D000000970",
            "D000004791"
      ],
      "InterventionAncestorTerm": [
            "Antimetabolites, Antineoplastic",
            "Antimetabolites",
            "Molecular Mechanisms of Pharmacological Action",
            "Antineoplastic Agents",
            "Enzyme Inhibitors"
      ],
      "InterventionArmGroupLabel": [
            "Experimental group",
            "Control group",
            "Experimental group"
      ],
      "InterventionBrowseBranchAbbrev": [
            "ANeo",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Antineoplastic Agents",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [
            "Learning"
      ],
      "InterventionBrowseLeafId": [
            "M1697",
            "M3433"
      ],
      "InterventionBrowseLeafName": [
            "Decitabine",
            "Antimetabolites"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "low"
      ],
      "InterventionDescription": [
            "Experimental group receive Allogeneic umbilical cord mesenchymal stem cell\uff0ci.v (SCLnow 19#)",
            "Decitabine\uff0c20mg/m^2/d"
      ],
      "InterventionMeshId": [
            "D000077209"
      ],
      "InterventionMeshTerm": [
            "Decitabine"
      ],
      "InterventionName": [
            "Allogeneic umbilical cord mesenchymal stem cells",
            "Decitabine"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Myelodysplastic Syndromes",
            "mesenchymal stem cells"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "May 9, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "May 5, 2022"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Sclnow Biotechnology Co., Ltd."
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Hohhot"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "China"
      ],
      "LocationFacility": [
            "Inner Mongolia International Mongolian Hospital"
      ],
      "LocationState": [
            "Inner Mongolia"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "010065"
      ],
      "MaximumAge": [
            "85 Years"
      ],
      "MinimumAge": [
            "60 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Research for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Myelodysplastic Syndrome (MDS)"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Sclnow Biotechnology Co., Ltd."
      ],
      "OrgStudyId": [
            "SCLnow-IMIMH-03"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Inner Mongolia International Mongolian Hospital",
            "China-Japan Union Hospital, Jilin University"
      ],
      "OverallOfficialName": [
            "Shana Chen",
            "Lei Guo"
      ],
      "OverallOfficialRole": [
            "Study Director",
            "Study Chair"
      ],
      "OverallStatus": [
            "Suspended"
      ],
      "OversightHasDMC": [],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 2022"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "patients will be monitored for any adverse events resulting from the treatment of Human Umbilical Cord Mesenchymal Stem Cells"
      ],
      "PrimaryOutcomeMeasure": [
            "Treatment related-adverse events counting"
      ],
      "PrimaryOutcomeTimeFrame": [
            "16 weeks"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "According to 'Diagnostic and Curative Criteria of Hematological Diseases' 3rd edition edited by Zhang Zhinan and Shen Di, evaluate the hUC-MSCs efficacy. The result as follow:\n\ncomplete remission (CR);\npartial remission (PR);\nstable disease (SD);\nprogressive disease (PD)"
      ],
      "SecondaryOutcomeMeasure": [
            "Improvement in clinical function"
      ],
      "SecondaryOutcomeTimeFrame": [
            "16 weeks"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "June 2022"
      ],
      "StartDateType": [
            "Anticipated"
      ],
      "StatusVerifiedDate": [
            "January 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "June 14, 2017"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "June 6, 2017"
      ],
      "StudyFirstSubmitQCDate": [
            "June 11, 2017"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": [
            "Others"
      ]
}